MX2016015577A - La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal. - Google Patents

La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.

Info

Publication number
MX2016015577A
MX2016015577A MX2016015577A MX2016015577A MX2016015577A MX 2016015577 A MX2016015577 A MX 2016015577A MX 2016015577 A MX2016015577 A MX 2016015577A MX 2016015577 A MX2016015577 A MX 2016015577A MX 2016015577 A MX2016015577 A MX 2016015577A
Authority
MX
Mexico
Prior art keywords
theobromine
derivatives
prevention
treatment
renal lithiasis
Prior art date
Application number
MX2016015577A
Other languages
English (en)
Inventor
Grases Freixedas Félix
COSTA BAUZÁ Antonia
María PRIETO ALMIRALL Rafael
Rodríguez Rodríguez Adrián
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of MX2016015577A publication Critical patent/MX2016015577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de la teobromina o sus derivados como inhibidor de la cristalización del ácido úrico para evitar la formación de cristales de ácido úrico en orina y como consecuencia la litiasis renal o en particular la litiasis renal úrica.
MX2016015577A 2014-05-29 2015-04-15 La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal. MX2016015577A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430819A ES2552706B1 (es) 2014-05-29 2014-05-29 La teobromina y sus derivados para el tratamiento o prevenciónde la litiasis renal
PCT/ES2015/070301 WO2015181412A1 (es) 2014-05-29 2015-04-15 La teobromina o sus derivados para el tratamiento o la prevención de la litiasis renal

Publications (1)

Publication Number Publication Date
MX2016015577A true MX2016015577A (es) 2018-03-01

Family

ID=53264679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015577A MX2016015577A (es) 2014-05-29 2015-04-15 La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.

Country Status (9)

Country Link
US (1) US10149851B2 (es)
EP (1) EP3150208B1 (es)
JP (1) JP6661551B2 (es)
KR (1) KR20170005020A (es)
CN (1) CN106456646B (es)
CA (1) CA2950036A1 (es)
ES (2) ES2552706B1 (es)
MX (1) MX2016015577A (es)
WO (1) WO2015181412A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017114843A1 (en) * 2015-12-29 2017-07-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Xanthine derivative inhibitors of bet proteins
ES2728434B2 (es) * 2018-04-20 2020-02-24 Univ Illes Balears Inhibidores de la cristalización de la xantina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624205A (en) * 1967-04-25 1971-11-30 Burroughs Wellcome Co Treatment of hyperuricemia in humans
GB2284761A (en) * 1993-12-03 1995-06-21 Euro Celtique Sa Prophylactic treatment of asthma
HUP9700654A2 (hu) * 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
GB0719544D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
CA2798911C (en) * 2010-05-19 2018-07-03 Unilever Plc Theobromine for increasing hdl-cholesterol
ES2532210T3 (es) * 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat

Also Published As

Publication number Publication date
ES2552706B1 (es) 2016-09-13
WO2015181412A1 (es) 2015-12-03
JP2017516791A (ja) 2017-06-22
EP3150208B1 (en) 2023-08-16
KR20170005020A (ko) 2017-01-11
CN106456646B (zh) 2020-03-27
CN106456646A (zh) 2017-02-22
CA2950036A1 (en) 2015-12-03
US20170143724A1 (en) 2017-05-25
JP6661551B2 (ja) 2020-03-11
EP3150208A1 (en) 2017-04-05
ES2552706A1 (es) 2015-12-01
US10149851B2 (en) 2018-12-11
ES2965278T3 (es) 2024-04-11

Similar Documents

Publication Publication Date Title
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
HRP20190514T1 (hr) Derivati 5-[(piperazin-1-il)-3-okso-propil]-imidazolidin-2,4-diona kao adamts inhibitori za liječenje osteoartritisa
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3481819A4 (en) CONNECTIONS AND THE USE THEREOF TO REDUCE THE URIC ACID LEVEL
HK1232145A1 (zh) 雙功能化合物和用於降低尿酸水平的用途
EP3247704A4 (en) Bifunctional compounds and use for reducing uric acid levels
PL3632904T3 (pl) Inhibitory urat1 do pobudzania wydalania kwasu moczowego
MX2016012302A (es) Preparaciones combinadas de acidificantes urunarios e inhibidores de la cristalizacion y su aplicacion para el tratamiento o prevencion de la litiasis renal fosfatica o inducida por fosfato calcico.
EP3193610A4 (en) Selective nav1.7 inhibitors for the treatment of diabetes
MX2016015577A (es) La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.
WO2013155465A8 (en) Substituted xanthine derivatives
EP3305768A4 (en) SODIUM SALT OF HARNIC ACID TRANSPORTERMER AND CRYSTALLINE FORM THEREOF
SG11202001327RA (en) Composition for reducing serum uric acid level
HRP20181789T1 (hr) Kristal derivata azol benzena kao inhibitor ksantin oksidaze
EP3247761A4 (en) Use of hydroxyacid to reduce the localized corrosion potential of low dose hydrate inhibitors
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit
WO2014193696A3 (en) Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors
HK1244434A1 (zh) 尿酸性或痛風性疾病的預防或治療
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR